Ian Davis (Bluesky @profiand)
@Prof_IanD
Professor of medicine | medical oncologist | Head @EHCSMonash | Chair, @ANZUPtrials | husband, father, grandfather, blessed | want to make a positive difference
Happiness is an empty beach, the wind in your ears, your best friend by your side, and 0/8 feet on the ground

3. In a study where there are limited treatment options and survival with SOC is the order of months, a phase 3 trial that uses ORR or PFS as a primary endpoint is unacceptable. 4. Why is it still acceptable in 2025 to have phase 3 trials that do not permit cross over when OS is…
Two opinions that to my surprise are either unpopular or not widely held: 1. The control arm of a randomised trial should be best standard of care. 2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
Two opinions that to my surprise are either unpopular or not widely held: 1. The control arm of a randomised trial should be best standard of care. 2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
The Histamine Trees (Ocularus clawoutii) appear to be in full flower.
We have known for more than 20 years that chemotherapy has clinically significant efficacy in metastatic #ProstateCancer #pcsm, including improved overall survival. It has not stopped working just because new agents are available or are being tested.
Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 sciencedirect.com/science/articl… The Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where…
The #ANZUP25 ASM was full of insightful collaboration, demonstrating commitment to our mission. Huge thanks to our international guests, speakers, chairs, sponsors & co-convenors. Congratulations to our award winners and thanks to all who made this inspiring event a success.
Wordle 1,495 X/6 1000th game didn’t go so well. ⬜🟨🟨🟨🟨 🟨⬜🟩🟩🟩 ⬜🟩🟩🟩🟩 ⬜🟩🟩🟩🟩 ⬜🟩🟩🟩🟩 ⬜🟩🟩🟩🟩
Thank you @ANZUPtrials @Prof_IanD @doccharris @DrL_Krieger for the invitation to share my thoughts with the ANZUP audience and for such a warm hospitality. Had a fabulous time, met new colleagues, built foundations for new collaborations, and hopefully for better outcomes for our…
Cancer clinical trial participants, especially in urogenital & prostate trials, value strong team relationships, ongoing communication, and knowing their impact @PsyOnc @hagsie @Prof_IanD @DrCraigGedye onlinelibrary.wiley.com/doi/10.1002/po…
All great things come to an end…had a fantastic time at #ANZUP25 sharing ideas, connecting, and meeting friends Thank you @Weranja @Prof_IanD for the invite! @ANZUPtrials @EdmondMKwan @TiansterZhang
Technically none of these are correct @DrHWoo! #ANZUP25

@TiansterZhang caught me up on the last decade of #RCC research in 20 mins! @ANZUPtrials #anzup25
My brain has always annoyed me by reading “M1NED” as “mined” conjuring images of dangerous places to tread. I’m starting to think it was right all along. #RenalCellCarcinoma #KidneyCancer #kcsm #adjuvant #ANZUP25
@ChrisSweens1 with comprehensive landscape talk in only 5 mins (!!), highlighting the #DASLHiCAP darolutamide role for high risk #prostatecancer. Pending further follow up. @ANZUPtrials #ANZUP25
“I’m feeling a bit like Ernie and Bert.” Prof Lisa Horvath adjusting the microphones to accommodate Prof Jarad Martin @DocJarad. #ANZUP25

Correlative work is possibly our most important tool in clinical trials. Congrats to @EdmondMKwan & #TheraP team for this insightful pub on ctDNA burden & PTEN loss predicting responses to 177Lu-PSMA & reminding us of his why - the patients behind the data. @ANZUPtrials #ANZUP25
@LouiseEmmett giving updates of #ENZAP & #EVOLUTION trials — such important IITs to help us understand ideal use of 177Lu-PSMA in met #prostatecancer. Congrats to all within @ANZUPtrials who contributed to these trials! #ANZUP25
@oncology_bg reminds us to communicate clearly on both publications & end of life care, infused w a bit of humor & humanity. Checklist for RCT pubs: pubmed.ncbi.nlm.nih.gov/39914429/ @ANZUPtrials #ANZUP25
Steve Callister, chair of @PCFA (Platinum Sponsor of @ANZUPtrials #ANZUP25 and staunch long term supporter of ANZUP) reminds us in the opening session that for all the science, we are “in the people business.”

Official #ANZUP25 opening w a warm blessing & tribute from the aboriginal custodians of the lands from @Binowee, welcoming messages from @Prof_IanD @doccharris @DrL_Krieger @ANZUPtrials CEO @SamanthaROakes